A Phase II Study of Neihulizumab vs "Conventional Treatment" to Treat Steroid-refractory Acute Graft-vs-host Disease (Sr-aGvHD) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 06 Apr 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Neihulizumab (Primary) ; Alemtuzumab; Antithymocyte globulin; Basiliximab; Daclizumab; Denileukin diftitox; Etanercept; Infliximab; Inolimomab; Methotrexate; Mycophenolate mofetil; Pentostatin; Sirolimus
Indications Graft-versus-host disease
Focus Therapeutic Use
Sponsors AltruBio

22 Apr 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
04 Mar 2016 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com